Objectives: Exosomes are important mediators in intercellular communications and play a role in cancer progression and metastasis. Exosomal membranes are enriched in endosome-specific tetraspanins (CD9 and CD63). Here, we explored the expression of CD63 and CD9 utilizing immunohistochemistry in malignant and nonmalignant cells in 29 resected pancreatic specimens (RPSs) of mixed racial background.
P
ancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death from cancer in the United States; 53,070 new cases and 41,780 deaths are estimated to occur in 2016. 1 The prognosis of PDAC is notoriously poor, with a 5-year overall survival (OS) of 5%. 2 Early diagnosis of PDAC has been and continues to be a challenge. Metastasis to distant organs, invasion of surrounding vasculature, and resistance to available chemotherapy are major causes of treatment failure and poor prognosis. The progress in the treatment of PDAC is unsatisfactory, and that immensely motivates researchers to better understand tumor interaction with microenvironment, the process of metastasis to distant organs, and resistance to chemotherapy.
Extracellular vesicles (EVs) are secreted membrane-enclosed vesicles that include exosomes, microvesicles, apoptotic bodies, and other EV subsets. The biogenesis of exosomes is not clear; therefore, the term EVs is often used. 3 Exosomes are membranous nanovesicles (EVs of 30-150 nm diameter) of endocytic origin released by most cell types from diverse organisms. 4 They contain functional biomolecules including nucleic acids, lipids, and proteins and are released into the extracellular space and enter the circulation. [4] [5] [6] [7] Exosomal membranes are enriched in endosomespecific tetraspanins (CD9, CD63, CD81). Various other proteins have been identified to play a role in exosomes biogenesis (Alix, TSG101) and membrane transport and fusion (flotillin, GTPase). 8 Exosomes are secreted from cancer cells at higher rates compared with healthy cells. 9 Tumor exosomes are considered as an important mediator of intercellular communication and play pivotal roles in facilitating cancer progression and metastasis. 4 Tumor exosomes represent a central mediator of the tumor microenvironment and can promote angiogenesis, stromal remodeling, pathway activation, chemoresistance, and genetic intercellular exchange. 8 In PDAC cells, exosomes provided remarkable survival benefits to PDAC cells against gemcitabine treatment. Moreover, tumor exosomes can exert a broad array of detrimental effects on the immune system and mediate cancer-associated immunosuppressive microenvironment and help initiate premetastatic niche. 10, 11 We therefore set out to explore the expression pattern of exosomal markers, CD63 and CD9, in malignant and nonmalignant (premalignant, inflammatory, and normal) cells in resected pancreatic specimens by immunohistochemical staining.
MATERIALS AND METHODS

Pancreatic Tissue Collection
This study was conducted at the University of South Alabama Mitchell Cancer Institute in Mobile, Alabama. Patients included were identified through searching the pancreatic surgeon-specific registry at the University of South Alabama Medical Center. The University of South Alabama institutional review board approved this study, and the institutional review board-approved database provided a waiver of the requirement for informed consent and allowed for publication of deidentified data.
Immunohistochemical Analysis
Two 5 µm sections were obtained from every resected pancreatic specimen (RPS). One was obtained from the pathologic tissues (PTs), and one was obtained from the adjacent normal tissues (ANTs). To study the expression pattern of the exosomal markers (CD63 and CD9), immunohistochemical staining was performed. 12 In brief, the unstained slides were first deparaffinaized by using xylene (X1, 10 minutes; X2, 10 minutes) and subsequently hydrated by sequential incubation in ethanol (100% EtOH, 5 minutes; 70% EtOH, 5 minutes; 50% EtOH, 5 minutes; 30% EtOH, 5 minutes; rinse the slides in running water, 5 minutes). Thereafter, antigen retrieval was performed using Declokar chamber (Biocare Medical, Concord, Calif ) with 1X Declokar buffer (Biocare Medical) followed by blocking of the endogenous peroxidase by incubation with peroxidase 1 (Biocare Medical). Later tissue sections were blocked with Background Sniper (Biocare Medical) for 10 minutes and incubated with the primary antibodies against CD63 and CD9 (1:50 and 1:25, respectively) (mouse monoclonal; Abcam, Cambridge, Mass) overnight at 4°C. After incubation, sections were washed and incubated with recommended polymer and probe (Biocare Medical) according to the manufacturer's protocol. Immunoreactivity was visualized by DAB chromogen followed by hematoxylin counterstain. Tissue sections incubated with normal mouse IgG (Santa Cruz Biotechnology Inc, Dallas, Tex) served as negative control.
Scoring and Statistical Analysis
Two pathologists, independently, scored the staining of CD63 and CD9. The intensity of cytoplasmic staining was graded from 1 to 3 where 1 represent (weak), 2 (moderate), and 3 (strong). The percentage of stained cells was estimated on each section in 10% increments. For each tissue section, a multiplicative Quick score (Q score) was calculated by multiplying the percentage of positive cells by the intensity of the staining. 13 The average Q score was calculated for each section. Unpaired t-test was used for statistical analysis. Statistical significance was defined as P < 0.05, and all tests were 2-sided. Tests were performed using GraphPad Prism 6 (GraphPad Software, La Jolla, Calif ).
RESULTS
Between October 2013 and December 2015, searching the pancreatic surgeon-specific registry at the University of South Alabama Medical Center identified 29 patients who underwent pancreatic resection. The baseline characteristics of the patients are summarized in Table 1 . The median age was 59 years (range, 35-80 years). Seventeen patients (59%) were white, and 12 patients (41%) were black. Sixteen patients (55%) were females, whereas 13 patients (45%) were males. Ten patients (34.5%) had PDAC, 3 patients (10.3%) had ampullary adenocarcinoma, 4 patients (13.8%) had pancreatic neuroendocrine tumors, 6 patients had premalignant conditions. 3 patients (10.3%) had intraductal papillary mucinous neoplasm, 3 patients (10.3%) had pancreatic intraepithelial neoplasm, and 6 patients (21.6%) had acute/chronic pancreatitis.
The hematoxylin-eosin (H&E) staining and the expression of CD63 and CD9 in the malignant PTs (MPTs) and their ANTs are shown, respectively, in Figure 1 . The H&E staining for the expression of CD63 and CD9 in the premalignant PTs (PPTs) and their ANTs are shown, respectively, in Figure 2 . The H&E staining and the expression of CD63 and CD9 in the inflammatory PTs (IPTs) and their ANTs are shown, respectively, in Figure 3 .
The mean multiplicative Q scores for CD63 and CD9 are summarized in Table 2 . The mean Q score in the PTs compared with their ANTs is higher in CD63 (209 vs 154; P = 0.0041) and CD9 (72 vs 24; P = 0.0018) (Fig. 4A) . The mean Q score in the MPTs compared with their ANTs (malignant ANTs) is higher in CD63 (231 vs 129; P < 0.0001) and CD9 (85 vs 25; P = 0.0132) (Fig. 4B) . The mean Q score in the PPTs compared with their ANTs (premalignant ANTs) is higher in CD63 (218 vs 100; P = 0.52) and CD9 (76 vs 12; P = 0.0048) (Fig. 4C) . The mean Q score in the IPTs compared with their ANTs (inflammatory ANTs) is lower in CD63 (138 vs 177; P = 0.36). The mean Q score is equal in CD9 (30 vs 30; P = 0.88) (Fig. 4D) . The mean Q score in the MPTs compared with premalignant ANTs is higher in CD63 (231 vs 218; P = 0.68) and CD9 (85 vs 76; P = 0.812) (Fig. 4E) .
The patients included in our study represent heterogeneous patient population including patients with malignant (n = 17), premalignant (n = 6), and inflammatory (n = 6) conditions. Among the patients diagnosed as having malignant conditions, we explored the pathologic characteristics and survival data of patients with PDAC (n = 10). Given the small sample size, the presented data represent a descriptive summary. The data on patients with ampullary adenocarcinoma (n = 3) and pancreatic neuroendocrine tumors (n = 4) were not further explored because of very small sample size. The relationship between the Q score of CD9 and CD63 and tumor T stage, number of involved lymph nodes (LNs), tumor grade, the presence of lymphovascular invasion (LVI), perineural invasion (PNI), progression-free survival (PFS), and OS is shown in Table 3 . Two patients (patients 1 and 8) have received neoadjuvant chemotherapy prior to pancreatic resection. Four patients (patients 1, 5, 9, and 10) have not progressed yet and are still alive.
DISCUSSION
Extracellular vesicles are now being widely studied especially in cancer research. They include apoptotic bodies (500 nm to 3 mm), microvesicles (100 nm to 1 mm), and exosomes (30-150 nm). [14] [15] [16] Exosomes appear to contribute to a diverse range of biological processes, depending on the cell of origin and the conditions for secretion. Current evidence suggests that exosomes fuse with the plasma membrane of the recipient cell and release their contents into the target cell. 17, 18 Recent studies have shown that exosomes can be isolated in vivo in bodily fluids such as blood, urine, breast milk, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, and synovial fluid. Exosome isolation and identification are strongly based on electron microscopy (size and shape) and Western blotting for the existence of proteins markers that are involved in exosomal biogenesis such as biogenesis-related proteins (Alix, TSG101) and/or exosomal membrane tetraspanins (CD9, CD63, CD81). [19] [20] [21] [22] [23] [24] [25] In conventional histological sections, recognition of EVs is substantially limited by the resolving power of the light microscope, as their diameter usually falls below the limit of resolution. Furthermore, not only histological assessment but also conventional cell biology techniques including laser confocal microscopy or flow cytometry have substantial limitations when used for analysis of EVs. 26 Pancreatic ductal adenocarcinoma cell-derived exosomes play important roles in their pathobiology. They were shown to be involved in premetastatic niche formation by inducing fibrotic environment in the liver of naive mice. Their uptake by Kupffer cells caused transforming growth factor β secretion and up-regulation of fibronectin production by hepatic stellate. Macrophage migration inhibitory factor was highly expressed in PDAC-derived exosomes, and its blockade prevented premetastatic niche formation and metastasis. In patients with stage I PDAC, macrophage migration inhibitory factor was higher in exosomes from patients who later developed liver metastasis compared with other patients who did not. 10 Clinical data indicated that exosomal integrins could be used to predict organ-specific metastasis. Exosome proteomics revealed distinct integrin expression patterns and shed light on metastatic organotropism. The αvβ5 binds to Kupffer cells and is linked to liver metastasis. On the other hand, α6β1 and α6β4 bind to lung fibroblasts and epithelial cells and are linked to lung metastasis. Targeting those integrins decreased exosome uptake and consequently liver and lung metastasis.
11
Pancreatic ductal adenocarcinoma cell-derived exosomes facilitate the survival and proliferation of disseminated cells at metastatic sites through inhibition of RFXAP (transcription factor) expression via miR-212-3p, resulting in MCH II down-regulation and induction of tolerance of dendritic cells. 27 The development of resistance to cytotoxic chemotherapy and targeted therapy in patients with PDAC is inevitable. Cross talk between tumor and microenvironment is one recognized mechanism of acquired resistance. 28, 29 In an experiment, dynamic light scattering-based size distribution identified EVs of 3 different sizes, large (>1500 nm), medium (500-1500 nm), and small (100-300 nm). Treatment with large and medium vesicular fractions of conditioned media from gemcitabine-treated PDAC cells did not show any chemoprotective effect in PDAC cells, whereas smaller vesicular fraction provided remarkable survival benefits to PDAC cells against gemcitabine treatment. Immunoblotting was performed to examine the specific markers associated with EVs. Immunoblot data revealed that these active EVs are enriched with exosomal markers CD9 and CD63.
Our work indicates that the transformation of normal pancreatic tissues into PPTs and MPTs is associated with increased expression of both exosomal markers (CD63 and CD9) (Figs. 4A,  B) . The transformation of normal pancreatic tissues into PPT is associated with increased expression of the exosomal marker CD9 (Fig. 4C ). There is a trend toward increased expression of CD63, but the difference in CD63 expression between PPTs and their ANTs did not reach statistical significance (probably due to small sample size). The transformation of PPTs into MPTs was associated with a trend toward increased expression of exosomal markers (CD63 and CD9) (Fig. 4E ), but the difference in expression did not reach statistical significance (probably due to small sample size).
The exosomal markers CD9 and CD63 have been recognized as differentially expressed proteins that can be detected using 30, 31 The relationship between CD9 gene expression (using reverse transcriptasepolymerase chain reaction and IHC) and tumor pathologic characteristics was previously explored. There was no statistically significant relationship between CD9 gene expression and metastatic status. However, CD9 gene expression was associated with LN status (P = 0.028), tumor stage (P = 0.024), and histopathologic grading (P = 0.041); 36.8% of the N0 stage patients had 31 In the same study, the IHC for CD63 was positive in all cases, and the mRNA levels for CD63 in almost all pancreatic tumor were preserved, and no decreased gene expression was detected. In our study, the relationship between the Q score of CD9 and CD63 and tumor T stage, number of involved LNs, tumor grade, the presence of LVI, PNI, PFS, and OS is shown in Table 3 . Given the small sample size (n = 10), the presented data represent descriptive summary.
The correlation between CD9 gene expression (using reverse transcriptase-polymerase chain reaction and IHC) and survival was previously explored as well. Patients with low CD9 gene expression had a worse 1-year survival and median OS compared with patients with high CD9 gene expression (0% vs 25.5%, P = 0.0004) (226 vs 397 days, P = 0.018). In our study, the mean Q score in patients who progressed and died within 12 months of their time of diagnosis compared with those who progressed or died after 12 months of their time of diagnosis was lower in CD63 (225 vs 236, P = 0.91) and in CD9 (55 vs 98; P = 0.76). The noticeable trend in our study toward worse survival with lower mean Q score in CD9 is similar to the previously published report. The lack of statistical significance is probably due to small sample size. We are working on expanding our cohort to include patients with stage IV pancreatic adenocarcinoma to further explore and validate the correlation between exosomal markers CD63 and CD9 expression and PFS and OS.
The exosome-based therapy is an attractive strategy for targeted drug therapy. Utilizing exosomes to carry therapeutic drugs, proteins, microRNA, and other transferable materials is a step forward in fighting cancer. Engineering exosomes to recognize a specific target/organ in the body would improve on our progress with personalized medicine. This will help maximize treatment efficacy and reduce associated toxicity. Moreover, the interaction between the tumor and the immune system via exosomes is an additional target that might further revolutionize immunotherapy. Components for successful exosome-based drug delivery include choice of donor cell, therapeutic cargo, use of targeting peptide, loading method, and administration route. 32, 33 
CONCLUSIONS
Scientists and clinicians are actively looking for diagnostic and predictive biomarkers in patients with pancreatic adenocarcinoma. Exosomal markers are among the biomarkers that have been and continue to be an ongoing interest. The exosomal markers CD9 and CD63 have been recognized as differentially expressed proteins that can be detected using IHC among other modalities. Our work shed more light and provided qualitative assessment using the Q score to the differential expression of CD9 and CD63 among a spectrum of normal, inflammatory, premalignant, and malignant pancreatic cells using IHC. We have also demonstrated that, using the Q score, CD63 was differentially expressed in patients with PDAC. Sho et al 31 reported that the IHC for CD63 was positive in all cases, and the mRNA levels for CD63 in almost all pancreatic tumors were preserved, and no decreased gene expression was detected. Moreover, the noticeable trend in our study toward worse survival with lower mean Q score in CD9 is similar to a previously published report. The lack of statistical significance is probably due to small sample size.
